งานนำเสนอเรื่อง: "By Charung Muangchana MD, Ph.D. National Vaccine Committee Office (NVCO) July 26, 2009 Update on H1N1 2009 Vaccine Development."— ใบสำเนางานนำเสนอ:
By Charung Muangchana MD, Ph.D. National Vaccine Committee Office (NVCO) July 26, 2009 Update on H1N1 2009 Vaccine Development
WHO stated that a fully licensed swine flu vaccine might not be available until the end of 2009 Preparation of a vaccine against a new strain of flu is nothing new, but limitations on production capacity Only producing about half as much "yield" as expected Vaccine producers can normally produce about a billion doses of any single vaccine each year, so that "there would still be a huge global shortfall Countries which produce vaccines, 70 percent of which are in Europe, will delay sending swine flu vaccines to other countries as they may come under "tremendous pressure to protect their own citizens first," note some experts, even if it meant breaking contracts with purchasing nations Introduction
Two injections will be required 3 wks apart for the swine flu and a third will be needed for seasonal flu to provide maximum immunity Children younger than 9 yrs old will need 4 shots One shot probably gives little immunity, 10 to 20% at most People older than age 50 may have some immunity from prior exposures to a similar virus, and will only need one shot The seasonal flu vaccine is not believed to protect against the new strain
Clinical trial in USA Medical institutes across the United States will begin human trials for a new H1N1 flu vaccine starting in early August. After eight days their blood will be checked and after 21 days they will receive another dose. The clinical trials will enroll as many as 1,000 adults and children at 10 centers nationwide. The trials will measure the safety and effectiveness of the vaccine.
Clinical trial in Australia Melbourne-based company CSL Ltd. plans to test a vaccine for the H1N1 virus on 240 volunteers on July 30. The test will be conducted on healthy adults between the ages of 18-64. Participants will receive two shots three weeks apart and will undergo blood tests to determine if they are generating an appropriate immune response to the virus.
Target group for H1N1 vaccine* All countries should immunize (1) health care workers in the first block of the necessary Health infrastructure. Expert group recommends the following for consideration noting that countries need to consider the importance of specific orders from the conditions: –(2) pregnant women (especially 2 nd & 3 rd trimester)—increase risk of severe disease –(3) Aged over 6 months with a variety of chronic medical conditions including morbid obesity—to reduce morbidity & mortality –(4) Healthy young adults 15 to 49 years—to reduce morbidity & mortality –(5) Healthy children —to reduce transmission –(6) Healthy adults 50 to 64 years —to reduce morbidity & mortality –(7) healthy adults 65 years and above —to reduce morbidity & mortality *SAGE’s recommendations, July 7, 2009